"Cardiovascular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
| Descriptor ID |
D002317
|
| MeSH Number(s) |
D27.505.954.411
|
| Concept/Terms |
Cardiovascular Agents- Cardiovascular Agents
- Agents, Cardiovascular
- Cardiovascular Drugs
- Drugs, Cardiovascular
|
Below are MeSH descriptors whose meaning is more general than "Cardiovascular Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiovascular Agents".
This graph shows the total number of publications written about "Cardiovascular Agents" by people in this website by year, and whether "Cardiovascular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 3 | 5 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 3 | 4 | 7 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiovascular Agents" by people in Profiles.
-
Using Advanced Bioinformatics Tools to Identify Novel Therapeutic Candidates for Proliferative Vitreoretinopathy. Transl Vis Sci Technol. 2023 05 01; 12(5):19.
-
Contemporary Management Before Chronic Total Occlusion Percutaneous Coronary Interventions: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circ Cardiovasc Qual Outcomes. 2023 03; 16(3):e008949.
-
Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2022 03 08; 113:110464.
-
What can heart failure trialists learn from oncology trialists? Eur Heart J. 2021 06 21; 42(24):2373-2383.
-
Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy. Pacing Clin Electrophysiol. 2020 05; 43(5):527-533.
-
Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population. Curr Neurol Neurosci Rep. 2020 04 15; 20(5):10.
-
Impact of Race and Ethnicity on the Clinical and Angiographic Characteristics, Social Determinants of Health, and 1-Year Outcomes After Everolimus-Eluting Coronary Stent Procedures in Women. Circ Cardiovasc Interv. 2019 04; 12(4):e006918.
-
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity? Cardiovasc Drugs Ther. 2019 02; 33(1):87-95.
-
Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents. J Int Med Res. 2018 Aug; 46(8):3183-3194.
-
The Clinical Use of Ivabradine. J Am Coll Cardiol. 2017 Oct 03; 70(14):1777-1784.